NAT CELL BIO:李大力课题组开发高效胞嘧啶编辑器

2020-05-12 MedSci原创 MedSci原创

胞苷碱基编辑器是催化特定基因组位点上胞苷向胸苷转化的强大遗传工具,进一步提高编辑范围和效率对其更广泛的应用至关重要。

胞苷碱基编辑器是催化特定基因组位点上胞苷向胸苷转化的强大遗传工具,进一步提高编辑范围和效率对其更广泛的应用至关重要。

通过在Cas9 nickase和脱氨酶之间插入Rad51蛋白的非序列特异性单链DNA结合域,研究人员生产了一序列超胞苷碱基编辑体。在细胞系和小鼠胚胎中,其活性显著提高,编辑窗口向原核苷酸相邻方向扩展。

此外,与原有的eA3A-BE4max相比,hyeA3A-BE4max选择性地催化了TC碱基对中的胞苷转化,编辑范围更广,活性更高(高达257倍)。

此外,在不诱导血红蛋白γ基因启动子中的旁观者突变的情况下,hyeA3A-BE4max特异性地产生了C-T转换,模仿了一种天然存在的改善β-血红蛋白病的基因变异,提示改进后的碱基编辑剂具有治疗潜力。

 

原始出处:

Xiaohui Zhang et al. Increasing the efficiency and targeting range of cytidine base editors through fusion of a single-stranded DNA-binding protein domain, NAT CELL BIO (2020). 

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884311, encodeId=88e41884311f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 07 08:56:57 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871742, encodeId=58a218e1742df, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 26 15:56:57 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919073, encodeId=56f319190e345, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 29 10:56:57 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962038, encodeId=376c19620384b, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 11 18:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809516, encodeId=7366180951699, content=<a href='/topic/show?id=7fd283e596f' target=_blank style='color:#2F92EE;'>#胞嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83759, encryptionId=7fd283e596f, topicName=胞嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Wed Jan 20 13:56:57 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2020-10-07 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884311, encodeId=88e41884311f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 07 08:56:57 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871742, encodeId=58a218e1742df, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 26 15:56:57 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919073, encodeId=56f319190e345, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 29 10:56:57 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962038, encodeId=376c19620384b, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 11 18:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809516, encodeId=7366180951699, content=<a href='/topic/show?id=7fd283e596f' target=_blank style='color:#2F92EE;'>#胞嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83759, encryptionId=7fd283e596f, topicName=胞嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Wed Jan 20 13:56:57 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1884311, encodeId=88e41884311f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 07 08:56:57 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871742, encodeId=58a218e1742df, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 26 15:56:57 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919073, encodeId=56f319190e345, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 29 10:56:57 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962038, encodeId=376c19620384b, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 11 18:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809516, encodeId=7366180951699, content=<a href='/topic/show?id=7fd283e596f' target=_blank style='color:#2F92EE;'>#胞嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83759, encryptionId=7fd283e596f, topicName=胞嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Wed Jan 20 13:56:57 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2020-10-29 sunylz
  4. [GetPortalCommentsPageByObjectIdResponse(id=1884311, encodeId=88e41884311f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 07 08:56:57 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871742, encodeId=58a218e1742df, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 26 15:56:57 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919073, encodeId=56f319190e345, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 29 10:56:57 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962038, encodeId=376c19620384b, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 11 18:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809516, encodeId=7366180951699, content=<a href='/topic/show?id=7fd283e596f' target=_blank style='color:#2F92EE;'>#胞嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83759, encryptionId=7fd283e596f, topicName=胞嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Wed Jan 20 13:56:57 CST 2021, time=2021-01-20, status=1, ipAttribution=)]
    2020-10-11 维他命
  5. [GetPortalCommentsPageByObjectIdResponse(id=1884311, encodeId=88e41884311f9, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 07 08:56:57 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1871742, encodeId=58a218e1742df, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Sun Jul 26 15:56:57 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919073, encodeId=56f319190e345, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Oct 29 10:56:57 CST 2020, time=2020-10-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1962038, encodeId=376c19620384b, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Sun Oct 11 18:56:57 CST 2020, time=2020-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1809516, encodeId=7366180951699, content=<a href='/topic/show?id=7fd283e596f' target=_blank style='color:#2F92EE;'>#胞嘧啶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83759, encryptionId=7fd283e596f, topicName=胞嘧啶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=85df2500173, createdName=654699882_84926986, createdTime=Wed Jan 20 13:56:57 CST 2021, time=2021-01-20, status=1, ipAttribution=)]

相关资讯

Sci Transl Med:基因编辑患者的干细胞可逆转糖尿病

导言:研究人员使用从罕见Wolfram综合症患者的皮肤中产生的诱导性多能干细胞,将人类干细胞转化为产生胰岛素的细胞,并使用基因编辑工具CRISPR-Cas9进行校正导致该综合征的遗传缺陷。然后,他们将

Cell Res:基因编辑CRISPR能成为新冠病毒利器?

自新型冠状病毒(SARS-CoV-2)疫情爆发以来,随着专家们的竞相研究,目前已发现有作用的治疗药物包括核苷类似物瑞德西韦(remdesivir)、抗疟疾及自身免疫性疾病药物氯喹(chloroquine)、抗HIV药物洛匹那韦/利托那韦(lopinavir / ritonavir)等,然而这些药物对SARS-CoV-2的作用有限,且是否能有效对抗病毒的不同变体尚未知。 2月18日,来自哈佛医学院

Biogen以27亿美元与基因编辑公司Sangamo签署协议,再次在阿尔茨海默氏病领域巨额投资

Biogen在阿尔茨海默氏病领域进行了另一笔巨额投资,与基因编辑公司Sangamo签署了3.5亿美元的前期协议,以获得针对tau蛋白ST-501药物的权利。

世界第二例艾滋病治愈案例 干细胞移植、基因编辑或为艾滋病治疗提供新思路

艾滋病是一种由于感染HIV病毒而导致自身免疫能力缺陷的疾病,自1981年世界第一例艾滋病病毒感染者发现至今,短短30多年间,艾滋病在全球肆虐流行,已成为重大的公共卫生问题和社会问题,引起世界卫生组织及

全球在体CRISPR基因编辑完成患者给药

2020年3月4日,艾尔建(Allergan)和Editas Medicine联合宣布:CRISPR疗法AGN-151587(EDIT-101)治疗先天性黑蒙症10型(LCA10)的I/II期临床试验

CRISPR-HOT:新型基因编辑工具,实现人源类器官的荧光标记和可视化

2009年,荷兰的Hans Clevers团队在体外三维(3D)器官培养领域取得重大突破,成功地在体外培养出有自我更新能力、保持肠道腺窝绒毛状结构的小鼠肠道类器官。自此,类器官技术在人类科学研究发展史